Similarly, pharmacologic or genetic inactivation of GSK-3β restores the cytotoxicity of NK cells against acute myeloid leukemia (AML) cells [27], suggesting the benefit of GSK-3 inhibition in leukemia treatment. The gene discussed is GSK3B; the disease is acute myeloid leukemia.